For best viewing, use the latest versions of Google Chrome or Mozilla Firefox

PrEP Use in New York State
Daily HIV pre-exposure prophylaxis (PrEP) is a key component of New York's Ending the Epidemic Initiative. These data show trends in PrEP use in NYS beginning in 2014, by counting the number of individuals who filled PrEP prescriptions, as reported to Source Healthcare Analytics (Symphony) and the Medicaid Data Warehouse.
42,813
Total individuals with a PrEP prescription
| Jan 2014-Jun 2018
Select POPULATION
Select Region
Filters

Data source: Source Healthcare Analytics (Symphony) and the NYS Medicaid Data Warehouse (MDW)


  • NYS uses the Source Healthcare Analytics (Symphony) data to extract prescription data for all payors with the exception of Medicaid. The Medicaid data information is pulled separately from the NYS Medicaid Data Warehouse (MDW)
  • While Source Healthcare Analytics (Symphony) data contains over 90% of prescriptions dispensed nationally, this does not mean that the completeness of the PrEP prescriptions filled is at 90%. This is due to a lower level of completeness of medical claim information in Symphony, which the NYS PrEP algorithm relies on for excluding prescriptions for individuals with other conditions (HIV, HBV)
  • Age/gender/race/region were calculated as of the first half of 2017 until January-June 2017 report, and after that they were based on the latest information.
  • Region is based on residence of individual.
  • Claims and encounter data are subject to errors and omissions, specifically with regard to the race/ethnicity of individuals. Interpret with caution.

Additional Notes

  • Individuals counted if filled at least one Truvada prescription in a given analysis time period.
  • Count of individuals are not cumulative and cannot be aggregated across time periods. Counts pertain only to the 6 month time period within which they are measured.
  • Exclusions
    • Having a diagnosis of HIV (ICD-9 042 or V08 and ICD-10 B20 or Z21) which occurred on two separate encounters, 2 years prior to the first use of Truvada.
    • Having a diagnosis of chronic Hepatitis B infection which occurred on two separate encounters, 2 years prior to the first use of Truvada.
    • Having pharmacy claims for the following ARV agents during the analysis time period: W5C, W5I, W5J, W5K, W5L,W5M, W5N, W5P, W5Q, W5T, W5U, W5X, W5Z (therapeutic class).
    • Having pharmacy claims for the following HBV agents during the analysis time period: W5F and W5J (therapeutic class).
    • Having HIV diagnosis or HBV diagnosis during the analysis time period.

For more information on the NYS Medicaid Data Warehouse and Source Healthcare Analytics (Symphony) data, visit the ETE Dashboard Data Sources page.